文献速递认知障碍与痴呆

路易体痴呆伴心脏传导异常患者使用胆碱酯酶抑制剂

Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities.
PubMed 文献 · Lancet Neurol · 2026-01-01

路易体痴呆患者因自主神经功能障碍和神经退行性变常出现心脏传导异常所致心动过缓。胆碱酯酶抑制剂仍是改善认知和精神行为症状最有效的治疗,但常因担心心脏风险而被停用。随机临床试验和荟萃分析支持其心脏安全性良好,新证据挑战传统回避观念,提示此类患者可在心脏筛查和监测下安全使用。

要点

  • 路易体痴呆患者心动过缓常见,与自主神经功能障碍和神经退行性变相关。
  • 胆碱酯酶抑制剂仍是改善认知和精神行为症状最有效的治疗。
  • 新证据提示伴心脏异常的路易体痴呆患者可在监测下使用胆碱酯酶抑制剂。

核心结论

  • 新兴证据挑战传统回避胆碱酯酶抑制剂的观念,提示伴心脏异常的路易体痴呆患者也可使用而不增加主要心血管事件风险。

研究设计与样本

  • 本文为综述,整合随机临床试验和荟萃分析证据及务实专家意见。

主要发现

  • 随机临床试验和荟萃分析证据支持胆碱酯酶抑制剂在路易体痴呆中具有有利的心脏安全性。
  • 路易体痴呆患者中心脏传导异常所致心动过缓因自主神经功能障碍和神经退行性变而常见。
  • 胆碱酯酶抑制剂常因担心加重心脏风险而被停用。

临床怎么用

  • 整合现有证据与务实专家意见,结合心脏筛查和监测,可使伴心脏异常的路易体痴呆患者从胆碱酯酶抑制剂中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bradycardia due to cardiac conduction abnormalities is prevalent in patients with dementia with Lewy bodies possibly due to autonomic dysfunction and neurodegeneration. Cholinesterase inhibitors remain the most effective treatment for cognitive and neuropsychiatric symptoms in patients with dementia with Lewy bodies, but are often withheld due to concerns of potentially worsening cardiac risk. Randomised clinical trials and meta-analysis evidence support a favourable cardiac safety profile for cholinesterase inhibitors in dementia with Lewy bodies. Emerging evidence challenges the conventional avoidance of cholinesterase inhibitors in patients who have dementia with Lewy bodies and cardiac abnormalities, and suggests that these patients can also be treated with cholinesterase inhibitors without increasing the risk of major cardiovascular events. Integrating available evidence with a pragmatic, expert-informed approach, and cardiac screening and monitoring, can enable patients with dementia with Lewy bodies and cardiac abnormalities to benefit from cholinesterase inhibitors.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Kalam S, Stellman J, Bell R, et al. Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities. Lancet Neurol. 2026. PMID: 42586101. doi:10.1016/S1474-4422(26)00231-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。